Rocket Pharmaceuticals (RCKT) Projected to Post Earnings on Monday

Rocket Pharmaceuticals (NASDAQ:RCKT) is anticipated to release its Q2 2025 earnings data before the market opens on Monday, August 4th. Analysts expect Rocket Pharmaceuticals to post earnings of ($0.57) per share and revenue of $4.36 million for the quarter.

Rocket Pharmaceuticals (NASDAQ:RCKT) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.02. During the same period in the previous year, the firm earned ($0.66) earnings per share. On average, analysts expect Rocket Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Rocket Pharmaceuticals Price Performance

Shares of RCKT stock opened at $2.99 on Friday. Rocket Pharmaceuticals has a twelve month low of $2.19 and a twelve month high of $22.01. The stock has a market capitalization of $319.30 million, a price-to-earnings ratio of -1.14 and a beta of 0.65. The stock has a fifty day simple moving average of $2.97 and a two-hundred day simple moving average of $6.43. The company has a current ratio of 9.19, a quick ratio of 9.19 and a debt-to-equity ratio of 0.05.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Rocket Pharmaceuticals during the first quarter worth about $189,000. AQR Capital Management LLC lifted its holdings in shares of Rocket Pharmaceuticals by 148.4% during the first quarter. AQR Capital Management LLC now owns 163,622 shares of the biotechnology company’s stock worth $1,091,000 after purchasing an additional 97,758 shares during the period. Millennium Management LLC lifted its holdings in shares of Rocket Pharmaceuticals by 121.8% during the first quarter. Millennium Management LLC now owns 747,147 shares of the biotechnology company’s stock worth $4,983,000 after purchasing an additional 410,238 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Rocket Pharmaceuticals by 24.0% during the first quarter. Goldman Sachs Group Inc. now owns 995,690 shares of the biotechnology company’s stock worth $6,641,000 after purchasing an additional 192,905 shares during the period. 98.39% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have weighed in on RCKT. Leerink Partners reiterated a “market perform” rating and issued a $8.00 target price (down from $37.00) on shares of Rocket Pharmaceuticals in a report on Wednesday, May 28th. Morgan Stanley reissued an “equal weight” rating and issued a $7.00 price target on shares of Rocket Pharmaceuticals in a research report on Wednesday, May 28th. Cantor Fitzgerald boosted their price target on Rocket Pharmaceuticals from $20.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, May 16th. TD Cowen reissued a “hold” rating on shares of Rocket Pharmaceuticals in a research report on Tuesday, May 27th. Finally, Wedbush reissued an “outperform” rating and issued a $32.00 price target on shares of Rocket Pharmaceuticals in a research report on Friday, May 16th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Rocket Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $17.87.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.